JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2008; 51:256-260, doi:10.1016/j.jacc.2007.06.064
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View CVN Genuine Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gilard, M.
Right arrow Articles by Boschat, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gilard, M.
Right arrow Articles by Boschat, J.
Related Collections
Right arrowRelated Articles

CLINICAL RESEARCH: CLINICAL TRIAL

Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin

The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study

Martine Gilard, MD*,*, Bertrand Arnaud, PharmD{dagger}, Jean-Christophe Cornily, MD*, Grégoire Le Gal, MD§, Karine Lacut, MD{ddagger}, Geneviève Le Calvez, PharmD{dagger}, Jacques Mansourati, MD*, Dominique Mottier, MD§, Jean-François Abgrall, MD{dagger},1 and Jacques Boschat, MD*,1

* Department of Cardiology, Brest University Hospital, Brest, France
{dagger} Department of Hematology, INSERM 0502, Brest University Hospital, Brest, France
{ddagger} Center for Clinical Investigation, EA3878, Brest University Hospital, Brest, France
§ Department of Internal Medicine and Chest Diseases, Brest University Hospital, Brest, France.

Manuscript received March 19, 2007; revised manuscript received June 7, 2007, accepted June 12, 2007.

* Reprint requests and correspondence: Dr. Martine Gilard, Département de Cardiologie, CHU de la Cavale Blanche, Boulevard Tanguy Prigent, 29609 Brest Cédex, France. (Email: martine.gilard{at}chu-brest.fr).

Objectives: This trial sought to assess the influence of omeprazole on clopidogrel efficacy.

Background: Clopidogrel has proved its benefit in the treatment of atherothrombotic diseases. In a previous observational study, we found clopidogrel activity on platelets, tested by vasodilator-stimulated phosphoprotein (VASP) phosphorylation, to be diminished in patients receiving proton pump inhibitor (PPI) treatment.

Methods: In this double-blind placebo-controlled trial, all consecutive patients undergoing coronary artery stent implantation received aspirin (75 mg/day) and clopidogrel (loading dose, followed by 75 mg/day) and were randomized to receive either associated omeprazole (20 mg/day) or placebo for 7 days. Clopidogrel effect was tested on days 1 and 7 in both groups by measuring platelet phosphorylated-VASP expressed as a platelet reactivity index (PRI). Our main end point compared PRI value at the 7-day treatment period in the 2 groups.

Results: Data for 124 patients were analyzed. On day 1, mean PRI was 83.2% (standard deviation [SD] 5.6) and 83.9% (SD 4.6), respectively, in the placebo and omeprazole groups (p = NS), and on day 7, 39.8% (SD 15.4) and 51.4% (SD 16.4), respectively (p < 0.0001).

Results: Omeprazole significantly decreased clopidogrel inhibitory effect on platelet P2Y12 as assessed by VASP phosphorylation test. Aspirin-clopidogrel antiplatelet dual therapy is widely prescribed worldwide, with PPIs frequently associated to prevent gastrointestinal bleeding. The clinical impact of these results remains uncertain but merits further investigation. (OCLA: Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated to Aspirin; http://www.clinicaltrials.gov/ct2/show/NCT00349661; NCT00349661 [ClinicalTrials.gov] )

Abbreviations and Acronyms
  ADP = adenosine diphosphate
  MFI = mean fluorescence intensity
  PPI = proton pump inhibitor
  PRI = platelet reactivity index
  SD = standard deviation
  VASP = vasodilator-stimulated phosphoprotein


Related Articles

Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
Paul A. Gurbel, Wei C. Lau, and Udaya S. Tantry
J. Am. Coll. Cardiol. 2008 51: 261-263. [Full Text] [PDF]

Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A37-A38. [Full Text] [PDF]



This article has been cited by other articles:


Home page
JWatch GeneralHome page
Does Omeprazole Affect Antiplatelet Therapy?
Journal Watch (General), March 13, 2008; 2008(313): 8 - 8.
[Full Text]


Home page
JWatch GastroenterologyHome page
Clopidogrel, Omeprazole, and Upper GI Bleeding
Journal Watch Gastroenterology, March 7, 2008; 2008(307): 6 - 6.
[Full Text]


Home page
Journal Watch CardiologyHome page
Identification of an Omeprazole-Clopidogrel Interaction
Journal Watch Cardiology, February 20, 2008; 2008(220): 2 - 2.
[Full Text]


Home page
J Am Coll CardiolHome page
P. A. Gurbel, W. C. Lau, and U. S. Tantry
Omeprazole: A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
J. Am. Coll. Cardiol., January 22, 2008; 51(3): 261 - 263.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2008 by the American College of Cardiology Foundation.